Development and testing of particulate formulations for the nasal delivery of antibodies.
about
Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review.Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation.A comparative study on the physicochemical and biological stability of IgG1 and monoclonal antibodies during spray drying processRole of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces.Delivery of antigens used for vaccination: recent advances and challenges.
P2860
Development and testing of particulate formulations for the nasal delivery of antibodies.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Development and testing of particulate formulations for the nasal delivery of antibodies.
@ast
Development and testing of particulate formulations for the nasal delivery of antibodies.
@en
type
label
Development and testing of particulate formulations for the nasal delivery of antibodies.
@ast
Development and testing of particulate formulations for the nasal delivery of antibodies.
@en
prefLabel
Development and testing of particulate formulations for the nasal delivery of antibodies.
@ast
Development and testing of particulate formulations for the nasal delivery of antibodies.
@en
P2093
P1476
Development and testing of particulate formulations for the nasal delivery of antibodies.
@en
P2093
Oya H Alpar
Richard S Kaye
Tarlochan S Purewal
P304
P356
10.1016/J.JCONREL.2008.11.009
P407
P577
2008-11-24T00:00:00Z